Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Anywaine, Zacchaeus; Barry, Houreratou; Anzala, Omu; Mutua, Gaudensia; Sirima, Sodiomon B; Eholie, Serge; Kibuuka, Hannah; Bétard, Christine; Richert, Laura; Lacabaratz, Christine; +13 more... McElrath, M Juliana; De Rosa, Stephen C; Cohen, Kristen W; Shukarev, Georgi; Katwere, Michael; Robinson, Cynthia; Gaddah, Auguste; Heerwegh, Dirk; Bockstal, Viki; Luhn, Kerstin; Leyssen, Maarten; Thiébaut, Rodolphe; Douoguih, Macaya; EBL2002 Study group; (2022) Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS medicine, 19 (1). e1003865. ISSN 1549-1277 DOI: https://doi.org/10.1371/journal.pmed.1003865

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.pmed.1003865

Abstract

Item Type Article
Faculty and Department Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
PubMed ID 35015777
Elements ID 169775

Share

Download

Filename: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Af.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar